Navigation Links
Astrazeneca's Investigational Cancer Therapies Revealed at ASCO

CHICAGO, AstraZeneca today announced details of two new investigational cancer therapies at the American Society of Clinical Oncology (ASCO) meeting. AZD2281 (KU-0059436) is a small molecule inhibitor of Poly-ADP Ribose Polymerase (PARP).

PARP is an enzyme involved in Base Excision Repair which is a key pathway in the repair of DNA single-stranded breaks. Inhibiting this DNA repair mechanism, in tandem with a defective DNA repair gene like BRCA1 or BRCA2, is thought to lead to double-stranded DNA breaks that tumor cells are unable to repair, resulting in tumor cell death.

AZD2281 has been studied in a range of tumor types in Phase I studies. The study presented today at ASCO showed that treatment with AZD2281 led to inhibition of PARP functional activity in both surrogate and tumor tissue, and reported that strong signals were detected in hereditary ovarian cancer. Between 5% and 10% of all breast and ovarian cancers are believed to be associated with mutations in the BRCA1 or BRCA2 mutations.

Women with BRCA mutations are reported to have up to an 87% risk of developing breast cancer, and up to a 44% risk of developing ovarian cancer by the age of 70.Professor James Carmichael of AstraZeneca said, "We are delighted to be working with The Royal Marsden Hospital and Netherlands Cancer Institute (NKI) on this study, which is at the forefront of research into new targeted treatments for cancer.

The early results we have seen in patients with hereditary ovarian cancer have encouraged us to move rapidly into the next phase of development for this compound."AZD0530, another investigational compound in Phase II clinical development is an inhibitor of Src in tumours. Src was the first cancer-causing gene to be discovered in the 1970s. Src kinases are a family of molecules that play an important role in cancer growth, spread, apoptosis and cell proliferation.

By inhibiting Src it is hoped that cancer prog
'"/>




Page: 1 2 3

Related medicine news :

1. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
2. New Drug Application Submitted for Investigational Antibiotic Doripenem
3. Fibroids unlikely to Turn Cancerous
4. Virus Level could Predict Cervical Cancer Risk
5. Cancer Doctors Okays Controversial Prostate Therapy
6. Potential New Cancer Gene Identified
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Cancer drugs in development nearly doubled since 1995
Post Your Comments:
(Date:10/13/2008)...ontinuing Commitment by Financing All Cash Transa... Generation Enterprise ...ewswire-FirstCall/ -- Health,Systems Solutions, In...sdaq: EMAG ) today announced the signing of a def...tock of Emageon. The agreement was unanimously,app...
(Date:10/13/2008)... NSAID pain relievers, experts say , , ...killer Vioxx was pulled from the market in 2004 --... attack, stroke and death -- many assumed that sto... study finds that "the risk was increased close to... a year," said co-author Dr. Robert Bresalier, a p...
(Date:10/13/2008)...ng programs for inpatients that include follow-up ... improve patients, ability to stay smoke-free. An...t hospitals around the world finds that efforts fe...,s chances of success by 65 percent. The study l...arch and Treatment Center at Massachusetts General...
(Date:10/13/2008)...t the combination of low plasma levels of antioxid...iated with certain forms of the eye disease age-re...eport in the October issue of Archives of Ophthal..."The retina is vulnerable to the damaging effects ...tion in the article. "While wavelengths in the UV ...
Breaking Medicine News(10 mins):Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 2Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 3Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 4Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 5Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 6Health News:Vioxx's Heart Risk Lingered Long After Use Ended 2Health News:Vioxx's Heart Risk Lingered Long After Use Ended 3Health News:Intensive support programs can help hospitalized smokers stay smoke-free 2Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2
...ue Lady, known as a jewel in the French shipping i... Alang, the world’s biggest breaking yard, in the ...r, this ship has come to India to be scrapped. Env...this move, due to the fear of toxic waste that wil...
... stress that some students experience while taking...system, more so if they have an allergy// , scient...arolinska Institutet in Stockholm examined how a m...hormone levels, the immune system and lung functio...
...ral judge in the US has ruled on Thursday that tob...low tar' cigarettes.// The judge though did rule ...o refuse any force towards the payment of any cost...S District Judge Gladys Kessler was quoted as sayi...
...ctive in Australia that hospitals seek parental co...aised concerns that there may be a decrease// in t...g any disease. A State Government report said tha...y took written consent instead of verbal consent p...
Other Medicine News:
(Date:10/13/2008)...r Populations Facilitates ...Newswire/ -- Rubicon Genomics, Inc. today,announce...samples for The,Cancer Atlas Genome Project., Rub...ize total genomic,DNA from 3,000 tissue and blood ...ex(TM) Whole Genome Amplification technology was j...
(Date:10/10/2008).../-,XTENT, Inc. (Nasdaq: XT...-term follow-up data from the CUSTOM I, II and III...esearch Foundation,s (CRF) twentieth annual,Transc...in Washington, DC.,The CUSTOM clinical trials are ...fety and efficacy of the Custom NX(R) drug eluting...
(Date:10/10/2008)... TriReme Medical Inc. (TMI),announced today that i...Europeenne) marking and commercialize in Europe th... vessel stent system specially designed for use,at... next generation in bifurcation stenting, the,Anta...he 2.2 million,angioplasty procedures performed an...
(Date:10/9/2008)...vigenics, Affymetrix and,Microsoft team on groundb...re/ -- A consortium of health care,technology and...-its-kind,research study to assess the behavioral ...hoose to receive such screenings to identify their... Sponsored by Scripps Translational Science Instit...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Risks for painkiller abuse do not outweigh benefits in chronic pain 18901 1Risks for painkiller abuse do not outweigh benefits in chronic pain 18901 2Drink Tea Win 2420 000 Experience the Calm A Sutra of Tea 18899 1Drink Tea Win 2420 000 Experience the Calm A Sutra of Tea 18899 2Drink Tea Win 2420 000 Experience the Calm A Sutra of Tea 18899 3Miami Rolls Out the Red Carpet for Latin Star Studded FedEx St Jude Gala 18897 1Miami Rolls Out the Red Carpet for Latin Star Studded FedEx St Jude Gala 18897 2Miami Rolls Out the Red Carpet for Latin Star Studded FedEx St Jude Gala 18897 3Amber Valletta on Preventing Mercury Exposure 18895 1Amber Valletta on Preventing Mercury Exposure 18895 2Amber Valletta on Preventing Mercury Exposure 18895 3
...esults from phase III,clinical trials and further ...6th Congress of the European Academy of,Dermatolog...he,efficacy and safety profile of alitretinoin as ... with severe refractory chronic,hand eczema. , Cur...ronic Hand,Eczema (CHE) refractory or unresponsive...
...1, 2007 - Gilead Sciences,Inc. (Nasdaq:GILD) toda...ating ambrisentan, an investigational endothelin r...ents with pulmonary,arterial hypertension (PAH). T...ly participated in the two pivotal Phase III ARIES... who had,previously discontinued other ERAs becaus...
Other Medicine Technology:Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 2Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 3Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 4Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 5Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 6
Ferris Smith Rongeurs, 12 overall length 300 mm.
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse.
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse.
It is designed for rigid skeletal fixation, and allows the surgeon greater freedom in positioning the fixation pins. The 3-point rigid skeletal fixation is designed for the supine, prone, lateral, or
Medicine Products: